Profile of ranibizumab: Efficacy and safety for the treatment of wet age-related macular degeneration

Therapeutics and Clinical Risk Management

Volumn 8, Issue , 2012, Pages 343-351

  Chen, Youxin ^a   Han, Fei ^a  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

Author keywords

Age related macular degeneration; Choroidal neovascularization; Efficacy; Ranibizumab; Safety

Indexed keywords

RANIBIZUMAB; VASCULOTROPIN A; VERTEPORFIN;

BLOOD VESSEL PERMEABILITY; CATARACT; CEREBROVASCULAR ACCIDENT; CONJUNCTIVAL HEMORRHAGE; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TOLERABILITY; ECCHYMOSIS; ENDOPHTHALMITIS; EYE FUNDUS; EYE INFLAMMATION; GASTROINTESTINAL HEMORRHAGE; HEART FAILURE; HEART INFARCTION; HEMATOMA; HUMAN; IMMUNOREACTIVITY; INTRAOCULAR HYPERTENSION; MONOTHERAPY; NONHUMAN; OPTICAL COHERENCE TOMOGRAPHY; PATHOGENESIS; PATIENT MONITORING; PATIENT SATISFACTION; PHOTODYNAMIC THERAPY; RETINA MACULA AGE RELATED DEGENERATION; RETINA MACULA EDEMA; RETINA TEAR; REVIEW; RISK BENEFIT ANALYSIS; RISK REDUCTION; SUBDURAL HEMATOMA; SUBRETINAL NEOVASCULARIZATION; TREATMENT DURATION; VAGINA BLEEDING; VISUAL ACUITY; VISUAL IMPAIRMENT;

EID: 84874916844     PISSN: 11766336     EISSN: 1178203X     Source Type: Journal    
DOI: 10.2147/TCRM.S32801     Document Type: Review

References (48)

1. Seddon JM, Chen CA. The epidemiology of age-related macular degeneration. Int Ophthalmol Clin. 2004;44:17-39.
2. Bressler NM. Age-related macular degeneration is the leading cause of blindness. JAMA. 2004;291:1900-1901.
3. Ferris FL 3rd, Fine SL, Hyman L. Age-related macular degeneration and blindness due to neovascular maculopathy. Arch Ophthalmol. 1984;102:1640-1642.
4. Funk M, Karl D, Georgopoulos M. Neovascular age-related macular degeneration: intraocular cytokines and growth factors and the influence of therapy with ranibizumab. Ophthalmology. 2009;116: 2393-2399.
5. Das A, McGuire PG. Retinal and choroidal angiogenesis: pathophysiology and strategies for inhibition. Prog Retin Eye Res. 2003;22:721-748.
6. Tong JP, Chan WM, Liu DT, et al. Aqueous humor levels of vascular endothelial growth factor and pigment epithelium-derived factor in polypoidal choroidal vasculopathy and choroidal neovascularization. Am J Ophthalmol. 2006;141:456-462.
7. Gaudreault J, Fei D, Rusit J, et al. Preclinical pharmacokinetics of ranibizumab (rhuFabV2) after a single intravitreal administration. Invest Ophthalmol Vis Sci. 2005;46:726-733.
8. Blick SKA, Keating GM, Wagstaff AJ. Ranibizumab. Drugs. 2007;67:1199-1206.
9. Lucentis (ranibizumab injection). Full prescribing information. South San Francisco, CA: Genentech, Inc; Jun 2010.
10. Ferrara N, Damico L, Shams N, et al. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina. 2006;26:859-870.
11. Ferrara N. Vascular endothelial growth factor and age-related macular degeneration: from basic science to therapy. Nat Med. 2010;16:1107-1111.
12. Lowe J, Araujo J, Yang J, et al. Ranibizumab inhibits multiple forms of biologically active vascular endothelial growth factor in vitro and in vivo. Exp Eye Res. 2007;85:425-430.
13. European Medicines Agency. Assessment report for Lucentis (ranibizumab). Procedure no: EMEA/H/C/000715/II/0020 [online]. Available from URL: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/000715/WC500101009.pdf. Accessed May 17, 2012.
14. Tolentino M. Systemic and ocular safety of intravitreal anti-VEGF therapies for ocular neovascular disease. Surv Ophthalmol. 2011;56(2):95-113.
15. Center for Drug Evaluation and Research. BLA application number: 125156. Clinical pharmacology and biopharmaceutics review(s) [online]. Available from URL: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/125156s0000_Lucentis_ClinPharmR.pdf. Accessed September 16, 2011.
16. Klein ML, Jorizzo PA, Watzke RC. Growth features of choroidal neovascular membranes in age-related macular degeneration. Ophthalmology. 1989;96:1416-1419.
17. Arias L, Armada F, Donate J, et al. Delay in treating age-related macular degeneration in Spain is associated with progressive vision loss. Eye. 2009;23:326-333.
18. Muether PS, Hermann MM, Koch K, et al. Delay between medical indication to anti-VEGF treatment in age-related macular degeneration can result in a loss of visual acuity. Graefe's Arch Clin Exp Ophthalmol. 2011;249:633-637.
19. Matthe E, Sandner D. Early treatment of exudative age-related macular degeneration with ranibizumab (Lucentis): the key to success. Ophthalmology. 2011;108:237-243.
20. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355: 1419-1431.
21. Kaiser PK, Brown DM, Zhang K, et al. Ranibizumab for predominantly classic neovascular age-related macular degeneration: subgroup analysis of first-year ANCHOR results. Am J Ophthalmol. 2007;144: 850-857.
22. Brown DM, Michels M, Kaiser PK, et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology. 2009;116:57-65.
23. Regillo CD, Brown DM, Abraham P, et al. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 1. Am J Ophthalmol. 2008;145:239-248.
24. Abraham P, Yue H, Wilson L, et al. Randomized, double-masked, sham- controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study Year 2. Am J Ophthalmol. 2010;150: 315-324.
25. Boyer DS, Heier JS, Brown DM, et al. A phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration. Ophthalmology. 2009;116: 1731-1739.
26. Schmidt-Erfurth U, Eldem B, Guymet R, et al. Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE study. Ophthalmology. 2011;118:831-839.
27. Fung AE, Lalwani GA, Rosenfeld PJ, et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol. 2007;143:566-583.
28. Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: the SUSTAIN study. Ophthalmology. 2011;118:663-671.
29. CATT Research Group. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: 2-year results. Ophthalmology. May 1, 2012. [Epub ahead of print.]
30. Monés J. A review of ranibizumab clinical trial data in exudative age-related macular degeneration and how to translate it into daily practice. Ophthalmologica. 2011;225:112-119.
31. Kaiser PK, Brown DM, Zhang K, et al. Ranibizumab for predominantly classic neovascular age-related macular degeneration: subgroup analysis of first-year ANCHOR results. Am J Ophthalmol. 2007;144: 850-857.
32. W, National Institute for Health and Clinical Excellence. Ranibizumab: the clinician's guide to commencing, continuing, and discontinuing treatment. Eye (Lond). 2009;23:2140-2142.
33. Antoszyk AN, Tuomi L, Chung CY, et al. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration. Am J Ophthalmol. 2008;145:862-874.
34. Schmidt-Erfurth U, Wolf S. Same-day administration of verteporfin and ranibizumab 0.5 mg in patients with choroidal neovascularization due to age-related macular degeneration. Br J Ophthalmol. 2008;92: 1628-1635.
35. Ley AM, et al. Combination therapy with verteporfin PDT and ranibizumab: twelve-month efficacy and safety results of the MONT BLANC study. Presented at AAO 2009; Abstract PA005.
36. Fintak DR, Shah GK, Blinder KJ, et al. Incidence of endophthalmitis related to intravitreal injection of bevacizumab and ranibizumab. Retina. 2008;28:1395-1399.
37. Koh A, Lim TH, Au Eong K, et al. Optimising the management of choroidal neovascularization in Asian patients: consensus on treatment recommendations for anti-VEGF therapy. Singapore Med J. 2011;52: 232-240.
38. Chang LK, Sarraf D. Tears of the retinal pigment epithelium: an old problem in a new era. Retina. 2007;27:523-534.
39. Chiang A, Chang LK, Yu F, et al. Predictors of anti-VEGF-associated retinal pigment epithelial tear using FA and OCT analysis. Retina. 2008;28:1265-1269.
40. Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev. 1997;18:4-25.
41. Gillies MC, Wong TY. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2007;356:748-749; author reply 749-750.
42. Boyer DS, Chung CY, Tuomi L. A safety overview of ranibizumab in patients with wet AMD: ANCHOR, MARINA, PIER, and SAILOR Studies. Presented at the American Academy of Ophthalmology (AAO) 2008 Annual Meeting, Atlanta, Georgia, US. November 8-11, 2008.
43. Ueta T, Yanagi Y, Tamaki Y, et al. Cerebrovascular accidents in ranibizumab. Ophthalmology. 2009;116:362.
44. Fraser-Bell S, Wu J, Klein R, et al. Cardiovascular risk factors and age-related macular degeneration: the Los Angeles Latino Eye Study. Am J Ophthalmol. 2008;145:308-316.
45. Wilson PW, D'Agostino RB, Levy D, et al. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97: 1837-1847.
46. Singer MA, Awh CC, Sadda S, et al. HORIZON: an open-label extension trial of ranibizumab for choroidal neovascularization secondary to age-related macular degeneration. Ophthalmology. February 4, 2012. [Epub ahead of print.]
47. Frennesson C, Nilsson UL, Peebo BB, et al. Significant improvements in near vision, reading speed, central visual field and related quality of life after ranibizumab treatment of wet age-related macular degeneration. Acta Ophthalmol. 2010;88:420-425.
48. Chua PY, Mitrut I, Armbrecht AM, et al. Evaluating patient discomfort, anxiety, and fear before and after ranibizumab intravitreous injection for wet age-related macular degeneration. Arch Ophthalmol. 2009;127:939-940.